Pubdate: Mon, 24 Oct 2005 Source: Inland Valley Daily Bulletin (CA) Copyright: 2005 Inland Valley Daily Bulletin Contact: http://www.dailybulletin.com/Stories/0,1413,203%257E23145%257E,00.html Website: http://www.dailybulletin.com/ Details: http://www.mapinc.org/media/871 Author: Allan J. Comeau, Ph.D. COCAINE VS. METHAMPHETAMINE In the 2004 movie "Alien vs. Predator," teens (mostly) witnessed these film-favorite monsters in mortal combat, only to be stymied by a young (female, in this case) human scientist's raw determination and instinctual savvy. While preparing for this column, in a bit of a mind-wandering fantasy, I somehow imagined that the part of the Alien could be played, metaphorically speaking, by the drug cocaine (it comes mostly from outside the United States), while the part of the Predator could go to methamphetamine (made by local drug pushers). Our hero is UCLA neuroscientist and addiction researcher Thomas F. Newton, with a strong supporting, albeit all-male, cast research team. I'm sticking with the monster metaphor for good reason: surveys show that both methamphetamine and cocaine have a strong foothold on American users, especially teens. These drugs are destroying lives at this very moment. While less than 1 percent of teens have tried methamphetamine, nearly half of those are recent users, according to the National Survey on Drug Use and Health, released last month. About 2 million Americans 12 years and older are regular cocaine users, about one-fourth of them using the much more highly addictive form known as crack. Based on the presumptive similarities between the cocaine and methamphetamine molecules and the fact that both are stimulants and utilize the dopamine (pleasure) circuitry -- with some exceptions -- scientists have tended to think of their effects as somewhat alike. In the article "Cocaine and Methamphetamine Produce Different Patterns of Subjective and Cardiovascular Effects," recently published in the journal Pharmacology, Biochemistry and Behavior, Drs. Newton and colleagues share the results of a controlled study conducted at the Jane and Terry Semel Institute for Neuroscience and Human Behavior at UCLA. Newton et al found that, although both drugs are stimulants, cocaine and methamphetamine have distinctive patterns of subjective and cardiovascular arousal. The subjective effects of cocaine tend to peak and also tend to decline more rapidly than those caused by methamphetamine, whose subjective effects tend to rise more slowly and are more sustained than that of cocaine. Also, the cardiovascular effects (heart rate and blood pressure) of both drugs were found to have similar initial patterns, but methamphetamine?s effects last longer. I asked Dr. Newton to comment on the usefulness of this research. "The significance of this study," he said, "is that it shows that drugs that we thought worked more or less alike actually produce quite different effects." Newton added, "It underscores the importance of developing treatment aimed at specific medications as opposed to addiction generally." There are a lot of reasons why researchers and clinicians would want to know this kind of information. One would be to explain reported differences in drug-taking patterns among cocaine and methamphetamine users. The former, cocaine users, tend to binge, while methamphetamine users are more likely to consume on a daily basis, Newton writes. In this study, he points out that factors such as differences in drug half-life (the time it takes for one-half of the drug taken to be neutralized by the body) can make a difference. "For example," he says, "the effects of cocaine are pretty much gone in 20 minutes to a half hour at the longest, whereas the half-life of cocaine is 90 minutes at the shortest, which means that you have 80 percent of your blood level when your subjective effects have gone completely away. How that works is really not known." "Another important significance of the study," he said, "is that the effects of methamphetamine lasted longer than we expected, compared to what we saw for cocaine. Why these two drugs differ, on a molecular level, is really not clear." With each gain in knowledge, we can only hope that, somehow, there can be a parallel gain in lives saved and the quality of lives lived. Allan J. Comeau, Ph.D., is a psychologist on the clinical faculty at UCLA and a former president of the Inland Southern California Psychological Association. Write him at 2001 S. Barrington Ave., Suite 304, Los Angeles, CA 90025, or visit (http://www.drcomeau.com)www.drcomeau.com - --- MAP posted-by: Beth Wehrman